Ladiratuzumab Vedotin (SLC39A6

Ladiratuzumab Vedotin (SLC39A6) 抗体, 单克隆，Ladiratuzumab Vedotin (SLC39A6) Antibody, Monoclonal，Ladiratuzumab Vedotin (SLC39A6) 抗体, 单克隆,Ladiratuzumab Vedotin (SLC39A6) Antibody, Monoclonal

产品名称：Ladiratuzumab Vedotin (SLC39A6) 抗体, 单克隆-Ladiratuzumab Vedotin (SLC39A6) Antibody, Monoclonal

产品货号：PSI-10-864-0.1mg

产品规格：0.1mg

背景资料：Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) that we are developing for the treatment of breast cancer. Most metastatic breast cancers express LIV-1, which also has been detected in a number of other cancers, including melanoma, prostate, ovarian, uterine, and cervical cancers. Ladiratuzumab vedotin consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC agent is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response.

保存建议：Ladiratuzumab Vedotin (SLC39A6) 抗体, 单克隆-Ladiratuzumab Vedotin (SLC39A6) Antibody, MonoclonalStore at -80℃

应用类型：

点击：Ladiratuzumab Vedotin (SLC39A6) 抗体, 单克隆-Ladiratuzumab Vedotin (SLC39A6) Antibody, Monoclonal查看更详细产品说明，更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论，请点击查看艾美捷特色产品中心。